Brett Kaplan, M.D., M.B.A.
Chief Financial and Corporate Development Officer
Brett is Chief Financial and Corporate Development Officer of Chroma Medicine. He also serves as the Audit Committee Chair of Compass Therapeutics. Prior to joining Chroma, Brett was the Chief Financial Officer of Prevail Therapeutics, which was acquired by Eli Lilly in January 2021 for $940 million. While at Prevail Therapeutics, Brett raised $175 million, including leading the company's $125 million initial public offering. Previously, Brett worked at Evercore, where he most recently served as Managing Director and was involved in numerous strategic and financing transactions including advising Bristol-Myers Squibb on its acquisitions of Celgene and Amylin, Takeda on its acquisitions of Shire and of Ariad and the merger of Akebia and Keryx. His previous roles include serving as an Equity Research Analyst at Cowen and Company, Director of Corporate Development at Cubist Pharmaceuticals, a pharmaceutical company acquired by Merck & Co., Inc., Manager of Strategic Medical Marketing at Biopure Corporation and Manager of Corporate Development and Strategy at Eli Lilly and Company. Brett holds an M.B.B.Ch and an M.B.A. from the University of Witwatersrand.